Navigation Links
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
4. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. TorreyPines Therapeutics Reports Third Quarter 2007 Results
6. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
8. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
9. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):